{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T10:14:57Z","timestamp":1769163297632,"version":"3.49.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","heartlungcirc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart, Lung and Circulation"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.hlc.2020.03.008","type":"journal-article","created":{"date-parts":[[2020,4,9]],"date-time":"2020-04-09T07:55:11Z","timestamp":1586418911000},"page":"1688-1695","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Impact of Patient and Model of Care Factors on Titration and Tolerability of Sacubitril\/Valsartan: An Early Australian Real-World Experience"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3693-4561","authenticated-orcid":false,"given":"Alexander","family":"Dashwood","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cassandra","family":"Vale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaaheen","family":"Laher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7891-4377","authenticated-orcid":false,"given":"Fiona","family":"Chui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haunnah","family":"Rheault","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaclyn","family":"Gan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yee Weng","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.hlc.2020.03.008_bib1","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s12872-016-0208-4","article-title":"Prevalence of heart failure in Australia: a systematic review","volume":"16","author":"Sahle","year":"2016","journal-title":"BMC Cardiovasc Disord"},{"issue":"1","key":"10.1016\/j.hlc.2020.03.008_bib2","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1186\/s12913-016-1748-0","article-title":"Current and projected burden of heart failure in the Australian adult population: a substantive but still ill-defined major health issue","volume":"16","author":"Chan","year":"2016","journal-title":"BMC Health Serv Res"},{"issue":"11","key":"10.1016\/j.hlc.2020.03.008_bib3","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.hlc.2020.03.008_bib4","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1517\/14656566.2015.1000300","article-title":"LCZ696: a new paradigm for the treatment of heart failure?","volume":"16","author":"Minguet","year":"2015","journal-title":"Expert Opin Pharmacother"},{"issue":"10","key":"10.1016\/j.hlc.2020.03.008_bib5","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.hlc.2018.06.1042","article-title":"National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand: guidelines for the prevention, detection, and management of heart failure in Australia 2018","volume":"27","author":"Atherton","year":"2018","journal-title":"Heart Lung Circ"},{"issue":"1","key":"10.1016\/j.hlc.2020.03.008_bib6","doi-asserted-by":"crossref","first-page":"25","DOI":"10.15420\/cfr.2017:1:2","article-title":"Expert comment: is medication titration in heart failure too complex?","volume":"3","author":"Atherton","year":"2017","journal-title":"Card Fail Rev"},{"issue":"22","key":"10.1016\/j.hlc.2020.03.008_bib7","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1056\/NEJM200105313442201","article-title":"Effect of carvedilol on survival in severe chronic heart failure","volume":"344","author":"Packer","year":"2001","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.hlc.2020.03.008_bib8","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1093\/eurjhf\/hft134","article-title":"Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry","volume":"15","author":"Maggioni","year":"2013","journal-title":"Eur J Heart Fail"},{"issue":"19","key":"10.1016\/j.hlc.2020.03.008_bib9","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1016\/j.jacc.2019.02.015","article-title":"Titration of medical therapy for heart failure with reduced ejection fraction","volume":"73","author":"Greene","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.hlc.2020.03.008_bib10","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.ahj.2012.11.004","volume":"165","author":"Ambrosy","year":"2013","journal-title":"Am Heart J"},{"issue":"15","key":"10.1016\/j.hlc.2020.03.008_bib11","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1093\/eurheartj\/ehw570","article-title":"Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril\/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF","volume":"38","author":"Bohm","year":"2017","journal-title":"Eur Heart J"},{"issue":"9","key":"10.1016\/j.hlc.2020.03.008_bib12","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1002\/ejhf.548","article-title":"Initiating sacubitril\/valsartan (LCZ696) in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens","volume":"18","author":"Senni","year":"2016","journal-title":"Eur J Heart Fail"},{"issue":"5","key":"10.1016\/j.hlc.2020.03.008_bib13","doi-asserted-by":"crossref","first-page":"334","DOI":"10.5694\/mja12.10993","article-title":"Management of heart failure","volume":"199","author":"Krum","year":"2013","journal-title":"Med J Aust"},{"issue":"9377","key":"10.1016\/j.hlc.2020.03.008_bib14","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(03)13800-7","article-title":"Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial","volume":"362","author":"Poole-Wilson","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.hlc.2020.03.008_bib15","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ijcard.2016.04.084","article-title":"Prescribing and up-titration in recently hospitalized heart failure patients attending a disease management program","volume":"216","author":"Carroll","year":"2016","journal-title":"Int J Cardiol"},{"issue":"9386","key":"10.1016\/j.hlc.2020.03.008_bib16","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(03)14283-3","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial","volume":"362","author":"McMurray","year":"2003","journal-title":"Lancet"},{"issue":"9A","key":"10.1016\/j.hlc.2020.03.008_bib17","doi-asserted-by":"crossref","first-page":"2B","DOI":"10.1016\/j.amjcard.2005.03.002","article-title":"Hyponatremia in congestive heart failure","volume":"95","author":"Oren","year":"2005","journal-title":"Am J Cardiol"},{"issue":"1","key":"10.1016\/j.hlc.2020.03.008_bib18","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s10741-010-9193-3","article-title":"Significance of hyponatremia in heart failure","volume":"17","author":"Bettari","year":"2012","journal-title":"Heart Fail Rev"},{"issue":"5","key":"10.1016\/j.hlc.2020.03.008_bib19","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1161\/CIRCHEARTFAILURE.109.912683","article-title":"Comparison of medical therapy dosing in outpatients cared for in cardiology practices with heart failure and reduced ejection fraction with and without device therapy: report from IMPROVE HF","volume":"3","author":"Heywood","year":"2010","journal-title":"Circ Heart Fail"},{"issue":"10","key":"10.1016\/j.hlc.2020.03.008_bib20","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1002\/ejhf.580","article-title":"Efficacy of sacubitril\/valsartan vs. enalapril at lower than target doses in heart failure with reduced ejection fraction: the PARADIGM-HF trial","volume":"18","author":"Vardeny","year":"2016","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"10.1016\/j.hlc.2020.03.008_bib21","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.ahj.2004.04.006","article-title":"Beta-blocker therapy for heart failure outside the clinical trial setting: findings of a community-based registry","volume":"148","author":"Franciosa","year":"2004","journal-title":"Am Heart J"},{"issue":"7","key":"10.1016\/j.hlc.2020.03.008_bib22","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1001\/jamacardio.2016.2332","article-title":"Nurse-led titration of angiotensin-converting enzyme inhibitors, beta-adrenergic blocking agents, and angiotensin receptor blockers in patients with heart failure with reduced ejection fraction","volume":"1","author":"Driscoll","year":"2016","journal-title":"JAMA Cardiol"}],"container-title":["Heart, Lung and Circulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1443950620301049?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1443950620301049?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T18:01:59Z","timestamp":1761415319000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1443950620301049"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":22,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S1443950620301049"],"URL":"https:\/\/doi.org\/10.1016\/j.hlc.2020.03.008","relation":{},"ISSN":["1443-9506"],"issn-type":[{"value":"1443-9506","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of Patient and Model of Care Factors on Titration and Tolerability of Sacubitril\/Valsartan: An Early Australian Real-World Experience","name":"articletitle","label":"Article Title"},{"value":"Heart, Lung and Circulation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hlc.2020.03.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2020 Published by Elsevier B.V. on behalf of Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ). All rights reserved.","name":"copyright","label":"Copyright"}]}}